User shared 2-year finasteride results, showing maintenance without regrowth or further recession. Experienced ball ache for a month, but no other side effects.
A 19-year-old discusses feelings of envy towards men with full heads of hair, sharing their experience with hair loss since age 16. They have been using oral minoxidil and topical finasteride for two years, with initial improvement but continued shedding, and are considering switching to dutasteride.
Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.
The user has been using finasteride, vitamin D3, and zinc for 5.5 months and had a hair transplant 3.5 months ago, focusing on the hairline and crown. Some users see subtle improvements in hair density, suggesting adding minoxidil for better results.
The user experienced significant hair regrowth using finasteride, minoxidil, and microneedling, with plans to continue treatment. They are pleased with the results, noting increased hair density and a restored hairline.
A 19-year-old is experiencing diffuse thinning and has been on finasteride for 6 months, noticing a slower but still concerning rate of hair loss. They started taking 0.5mg of dutasteride once a week in addition to 1.25mg of finasteride on other days and are seeking advice on this treatment approach.
A user's progress in hair loss treatment after two months, using finasteride, minoxidil, dermabrasion and keto. They are tracking their progress by shaving their head every month to better track results.
The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.
KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.